Last update 08 May 2025
Centenaire Biosciences, Inc.

Centenaire Biosciences, Inc.

Private Company|2021|Gyeonggi-do, South Korea|
< 10
|
www.ctnbio.com

Overview

Tags

Neoplasms
Urogenital Diseases
Congenital Disorders
Monoclonal antibody
Antibody fusion proteins

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms7
Immune System Diseases1
Endocrinology and Metabolic Disease1
Hemic and Lymphatic Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Monoclonal antibody7
Antibody fusion proteins1
Top 5 TargetCount
FGFR3(Fibroblast growth factor receptor 3)1
MUC16(Mucin-16)1
HER2 x HER2 exon 201
CD33(Myeloid cell surface antigen CD33)1
EGFR x EGFRvIII1

Related

8
Drugs associated with Centenaire Biosciences, Inc.
CTN-005
Target
EGFR x c-Met
Mechanism
EGFR antagonists [+1]
Active Org.
Centenaire Biosciences, Inc.Centenaire Biosciences, Inc.
Originator Org.
Centenaire Biosciences, Inc.Centenaire Biosciences, Inc.
Active Indication
Non-Small Cell Lung Cancer
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
CTN-010
Target
OX40
Mechanism
OX40 inhibitors
Active Org.
Centenaire Biosciences, Inc.Centenaire Biosciences, Inc.
Originator Org.
Centenaire Biosciences, Inc.Centenaire Biosciences, Inc.
Active Indication
Dermatitis, Atopic
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
CTN-014
Target
EGFR x EGFRvIII
Mechanism
EGFR antagonists [+1]
Active Org.
Centenaire Biosciences, Inc.Centenaire Biosciences, Inc.
Originator Org.
Centenaire Biosciences, Inc.Centenaire Biosciences, Inc.
Active Indication
Glioblastoma
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Centenaire Biosciences, Inc.
Login to view more data
0 Patents (Medical) associated with Centenaire Biosciences, Inc.
Login to view more data
100 Deals associated with Centenaire Biosciences, Inc.
Login to view more data
100 Translational Medicine associated with Centenaire Biosciences, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
8
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
CTN-013
 ( MUC16 )		Ovarian Cancer
More
Preclinical
CTN-008
 ( CD33 )		Acute Myeloid Leukemia
More
Preclinical
CTN-001
 ( HER2 x HER2 exon 20 )		Neoplasms
More
Preclinical
CTN-005
 ( EGFR x c-Met )		Non-Small Cell Lung Cancer
More
Preclinical
CTN-002
 ( GPC3 )		Hepatocellular Carcinoma
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free